Leprosy.
D002991:Clofazimine / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003622:Dapsone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D014943:Global Health; D006801:Humans; D007391:International Cooperation; D007917:Leprostatic Agents / Q000627:therapeutic use*; D007918:Leprosy / Q000188:drug therapy* / Q000453:epidemiology*; D009164:Mycobacterium Infections / Q000188:drug therapy* / Q000453:epidemiology*; D009166:Mycobacterium leprae / Q000302:isolation & purification; D015995:Prevalence; D012293:Rifampin / Q000627:therapeutic use; D014944:World Health Organization